Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH.
OBJECTIVE
The ideal medication for treatment of acid related diseases should have a rapid onset of action to promote hemostasis. The aim of our study was to investigate the inhibitory effects on gastric acid secretion after single intravenous administrations of lansoprazole 30 mg and famotidine 20 mg.


METHODS
Twelve Helicobacter pylori-negative male subjects participated in this randomized, two-way crossover study. Intragastric pH was monitored continuously for 4 hours after single intravenous administration of lansoprazole 30 mg or famotidine 20 mg.


RESULTS
The average pH during the 4-hour period after administration of famotidine was higher than after lansoprazole (median: 5.15 versus 3.55, respectively; p = 0.0376). During the 4-hour study period, famotidine 20 mg provided a longer duration of pH > 3, 3.5, 4, 5, 6 and 7, compared to lansoprazole 30 mg (median: 73.6% versus 57.0%; p = 0.0414, 66.8% versus 47.8%; p = 0.0281, 60.8% versus 38.8%; p = 0.0150, 55.7% versus 29.7%; p = 0.0281, 45.0% versus 23.1%; p = 0.0414 and 23.9% versus 3.65%; p = 0.0076).


CONCLUSIONS
In Helicobacter pylori-negative healthy male subjects, an intravenous dose of famotidine 20 mg more rapidly increases intragastric pH than lansoprazole 30 mg.
Iida
Hiroshi
H
Gastroenterology Division, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Yokohama Kanagawa, 236-0004, Japan.
Inamori
Masahiko
M
Akimoto
Keiko
K
Mawatari
Hironori
H
Endo
Hiroki
H
Nozaki
Yuichi
Y
Akiyama
Tomoyuki
T
Ikeda
Tamon
T
Sakamoto
Yasunari
Y
Fujita
Koji
K
Yoneda
Kyoko
K
Takahashi
Hirokazu
H
Yoneda
Masato
M
Goto
Ayumu
A
Abe
Yasunobu
Y
Kobayashi
Noritoshi
N
Kirikoshi
Hiroyuki
H
Kubota
Kensuke
K
Saito
Satoru
S
Nakajima
Atsushi
A
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D018592:Cross-Over Studies; D065731:Cytochrome P-450 CYP2C19; D015738:Famotidine / Q000008:administration & dosage*; D005744:Gastric Acid / Q000378:metabolism*; D005838:Genotype; D006635:Histamine H2 Antagonists / Q000008:administration & dosage*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D064747:Lansoprazole; D008297:Male; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D064747:Lansoprazole; D015738:Famotidine; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19